HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer

Prostate cancer (CaP) is the most common cancer among adult men in the Western world. Better insight into its tumor-activating pathways may facilitate the development of targeted therapies. In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis. This is functionally relevant, as targeting Her2 activation to the murine prostate cooperates with Pten loss and drives CaP progression. Mechanistically, this is associated with activation of the MAPK pathway and abrogation of the Pten loss-induced cellular senescence program. Importantly, inhibition of MEK function strongly suppressed proliferation within these tumors by restoring the Pten loss-induced cellular senescence program. Taken together, these data suggest that stratification of CaP patients for HER2/3 and PTEN status could identify patients with aggressive CaP who may respond favorably to MEK inhibition.

[1]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[2]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[3]  J. Woodgett,et al.  β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation , 2011, Oncogene.

[4]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[5]  J. Clohessy,et al.  A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. , 2010, The Journal of clinical investigation.

[6]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[7]  Sylvain Meloche,et al.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy , 2010, Journal of hematology & oncology.

[8]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[9]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[10]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[11]  R. Cardiff,et al.  PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis* , 2009, The Journal of Biological Chemistry.

[12]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[13]  A. Gericke,et al.  Phosphorylation keeps PTEN phosphatase closed for business , 2009, Proceedings of the National Academy of Sciences.

[14]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[15]  M. Moasser.  Targeting the function of the HER2 oncogene in human cancer therapeutics , 2007, Oncogene.

[16]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[17]  Levi A Garraway,et al.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.

[18]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[19]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[20]  R. Montironi,et al.  HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. , 2006, Human pathology.

[21]  J. Terwilliger,et al.  Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. , 2006, Carcinogenesis.

[22]  I. H. Koumakpayi,et al.  Expression and Nuclear Localization of ErbB3 in Prostate Cancer , 2006, Clinical Cancer Research.

[23]  J. Bartlett,et al.  The Role of HER1-HER4 and EGFRvIII in Hormone-Refractory Prostate Cancer , 2006, Clinical Cancer Research.

[24]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[25]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[26]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[27]  T. Visakorpi,et al.  Molecular genetics of prostate cancer. , 2003, Annals of medicine.

[28]  R. Cardiff,et al.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. , 2003, Cancer research.

[29]  Liang Cheng,et al.  Evaluation of HER‐2/neu expression in prostatic adenocarcinoma , 2002, Cancer.

[30]  M. Jordá,et al.  Her2 expression in prostatic cancer: a comparison with mammary carcinoma. , 2002, The Journal of urology.

[31]  M. Groszer,et al.  Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.

[32]  F. Waldman,et al.  HER2 protein expression and gene amplification in androgen-independent prostate cancer. , 2001, American journal of clinical pathology.

[33]  P. Roy-Burman,et al.  Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation , 2001, Mechanisms of Development.

[34]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[35]  Caiying Guo,et al.  Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon cre‐mediated excision , 2000, Genesis.

[36]  P. Dahia,et al.  PTEN, a unique tumor suppressor gene. , 2000, Endocrine-related cancer.

[37]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[39]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[40]  J. Ross,et al.  Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma , 1997, Cancer.

[41]  A. Mes-Masson,et al.  Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. , 1996, Cancer letters.

[42]  M. Rifkin,et al.  Contribution of HER‐2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis , 1993, Cancer.

[43]  J. Moul,et al.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.

[44]  T. Visakorpi,et al.  Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[45]  P. Humphrey,et al.  Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. , 1992, Surgical oncology.

[46]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[47]  S. Maygarden,et al.  Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. , 1991, Human pathology.

[48]  J. Bartlett,et al.  HER2 and COX2 expression in human prostate cancer. , 2004, European journal of cancer.

[49]  S. Devesa,et al.  International trends and patterns of prostate cancer incidence and mortality , 2000, International journal of cancer.